Sigal Kremer-Tal

Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel.

OurCrowd Management Ltd (OurCrowd) is a venture capital firm founded in 2013 by Jonathan Medved and Steven Blumgart. The firm is headquartered in Jerusalem, Israel.

HIL Applied Medical Ltd. develops cancer Proton Therapy systems. It applies a patented approach, combining nanotechnology, and high-intensity lasers for its solutions. The company was founded by Shmuel Eisenmann and Arie Zigler in 2010 and is headquartered in Jerusalem, Israel.

Nanolabz, Inc. develops a technology system for cancer proton radiation therapy. It develops and sells laser physics targets for the short-pulse laser research and development sector. The company was founded by Steven Malekos, Jesse Adams, and Grant Korgan and is headquartered in Sparks, NV.

BrainQ Technologies Ltd. develops a detection and non-invasive treatment technology to help patients with paralysis move their limbs. The company was founded by Segal Yaron, Drechsler Yotam, and Shohami Emerita Esther on August 14, 2011 and is headquartered in Jerusalem, Israel.

DreaMed Diabetes Ltd. is a medical technology company based in Petach Tikva, Israel. DreaMed Diabetes is currently commercializing its endo.digital AI-based clinical decision support system for diabetes management. The endo.digital platform has FDA clearance for patients with type 1 diabetes using continuous glucose monitors or self-monitoring blood glucose monitor devices and insulin pumps. The technology also received expanded FDA clearance to include patients with type 1 or type 2 diabetes on multiple daily injections. The Israeli company's first product, an artificial pancreas technology, was licensed to Medtronic and incorporated into its 780g insulin pump technology. The company provides personalized diabetes treatment optimization solutions and was founded in 2014 by Revital Nimri, Tadej Battelino, Eran Atlas, Thomas Danne, and Ido Muller. Eran Atlas has been the CEO since 2014.

OurCrowd Medtech Fund invests in companies located in Israel. The fund targets operating in the fields of medical devices, therapeutics, medical robotics. It provides financing for early stage capital requirements.

OncoHost Ltd. is an Israeli technology company that combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. The company utilizes proprietary proteomic analysis to understand a patient's unique response to therapy and overcome resistance to therapy. OncoHost's host response profiling platform (Prophet®) analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to a given cancer therapy. OncoHost was founded in 2017, and the CEO is Ofer Sharon.